[1] DEFTEREOS S G, BEERKENS F J, SHAH B, et al. Colchicine in cardiovascular disease: In-depth review[J]. Circulation, 2022, 145(1): 61-78. doi:  10.1161/CIRCULATIONAHA.121.056171
[2] NIDORF S M, FIOLET A T L, MOSTERD A, et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med, 2020, 383(19): 1838-1847.
[3] TARDIF J C, KOUZ S, WATERS D D, et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med, 2019, 381(26): 2497-2505. doi:  10.1056/NEJMoa1912388
[4] ISLAM K, ISLAM R, NGUYEN I, et al. Diabetes mellitus and associated vascular disease: pathogenesis, complications, and evolving treatments[J]. Adv Ther, 2025, 42(6): 2659-2678.
[5] ZHANG F S, HE Q Z, QIN C H, et al. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review[J]. Acta Pharmacol Sin, 2022, 43(9): 2173-2190.
[6] VAIDYA K, TUCKER B, KURUP R, et al. Colchicine inhibits neutrophil extracellular trap formation in patients with acute coronary syndrome after percutaneous coronary intervention[J]. J Am Heart Assoc, 2021, 10(1): e018993.
[7] IMAZIO M, NIDORF M. Colchicine and the heart[J]. Eur Heart J, 2021, 42(28): 2745-2760.
[8] FERRUCCI L, FABBRI E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty[J]. Nat Rev Cardiol, 2018, 15(9): 505-522.
[9] TOMBETTI E, HYSA E, MASON J C, et al. Blood biomarkers for monitoring and prognosis of large vessel vasculitides[J]. Curr Rheumatol Rep, 2021, 23(3): 17.
[10] JOLLY S S, D’ENTREMONT M A, LEE S F, et al. Colchicine in acute myocardial infarction[J]. N Engl J Med, 2025, 392(7): 633-642.
[11] LI J J, MENG X, SHI F D, et al. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack(CHANCE-3): multicentre, double blind, randomised, placebo controlled trial[J]. BMJ, 2024, 385: e079061.
[12] KELLY P, LEMMENS R, WEIMAR C, et al. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke(CONVINCE): a randomised controlled trial[J]. Lancet, 2024, 404(10448): 125-133.
[13] GOSWAMI S K, RANJAN P, DUTTA R K, et al. Management of inflammation in cardiovascular diseases[J]. Pharmacol Res, 2021, 173: 105912.
[14] MASENGA S K, KABWE L S, CHAKULYA M, et al. Mechanisms of oxidative stress in metabolic syndrome[J]. Int J Mol Sci, 2023, 24(9): 7898.
[15] DE ROSA S, ARCIDIACONO B, CHIEFARI E, et al. Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links[J]. Front Endocrinol, 2018, 9: 2.
[16] ROUBILLE F, BOUABDALLAOUI N, KOUZ S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the colchicine cardiovascular outcomes trial(COLCOT)[J]. Diabetes Care, 2024, 47(3): 467-470.
[17] MOHAMMADNIA N, LOS J, OPSTAL T S J, et al. Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trial[J]. Front Cardiovasc Med, 2023, 10: 1244529.
[18] YEH J J, KUO I L, YIP H T, et al. Effects of colchicine use on ischemic and hemorrhagic stroke risk in diabetic patients with and without gout[J]. Sci Rep, 2022, 12(1): 9195.
[19] BAIER J M, FUNCK K L, VERNSTRØM L, et al. Colchicine mitigates arterial stiffness in high-risk patients with type 2 diabetes: a randomized placebo-controlled trial[J]. Eur J Prev Cardiol, 2025: zwaf143.
[20] KUZEMCZAK M, IBRAHEM A, ALKHALIL M. Colchicine in patients with coronary artery disease with or without diabetes mellitus: a meta-analysis of randomized clinical trials[J]. Clin Drug Investig, 2021, 41(8): 667-674.
[21] BELLINGE J W, FRANCIS R J, LEE S C, et al. The effect of vitamin-K1 and colchicine on vascular calcification activity in subjects with diabetes mellitus(ViKCoVaC): a double-blind 2x2 factorial randomized controlled trial[J]. J Nucl Cardiol, 2022, 29(4): 1855-1866.
[22] DEFTEREOS S, GIANNOPOULOS G, RAISAKIS K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients[J]. J Am Coll Cardiol, 2013, 61(16): 1679-1685.
[23] MA Z J, CHEN J, JIN K Q, et al. Colchicine and coronary heart disease risks: a meta-analysis of randomized controlled clinical trials[J]. Front Cardiovasc Med, 2022, 9: 947959.
[24] MASSON W, LOBO M, BARBAGELATA L, et al. Effect of anti-inflammatory therapy on major cardiovascular events in patients with diabetes: a meta-analysis[J]. Diabetes Metab Syndr, 2021, 15(4): 102164.
[25] RIBEIRO S A, LOPES C, AMARAL R, et al. The therapeutic potential of colchicine in the complications of COVID19. Could the immunometabolic properties of an old and cheap drug help?[J]. Metabol Open, 2020, 7: 100045.
[26] GONZÁLEZ L, BULNES J F, ORELLANA M P, et al. The role of colchicine in atherosclerosis: from bench to bedside[J]. Pharmaceutics, 2022, 14(7): 1395.
[27] ROBINSON P C, TERKELTAUB R, PILLINGER M H, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease[J]. Am J Med, 2022, 135(1): 32-38.
[28] LIU Y Q, LU X X, HU K X, et al. Dynamic observation of bone marrow suppression and chromosomal aberrations in patients with acute colchicine poisoning[J]. World J Emerg Med, 2022, 13(2): 130-134.
[29] BOCZAR K E, SHIN S, DEKEMP R A, et al. The Canadian study of arterial inflammation in patients with diabetes and recent vascular events, evaluation of colchicine effectiveness(CADENCE): protocol for a randomised, double-blind, placebo-controlled trial[J]. BMJ Open, 2023, 13(11): e074463.
[30] MIWA Y, MUTOH A, MORIMOTO T, et al. Effects of low-dose colchicine on serum high-sensitivity c-reactive protein level in coronary artery disease patients with type 2 diabetes mellitus and enhanced inflammatory response protocol for a randomized, double-blind, placebo-controlled, phase 2, dose-finding study[J]. Biomed Hub, 2022, 7(3): 156-164.